Cardiorenal safety and efficacy of angiotensin receptor-neprilysin inhibitors in heart failure across the ejection fraction spectrum: A meta-analysis and meta-regression of RCTs with 28,001 patients.

Rampengan, Derren D C H et al.·Biomedical reports·2026·
RPEP-159692026RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Cardiorenal safety and efficacy of angiotensin receptor-neprilysin inhibitors in heart failure across the ejection fraction spectrum: A meta-analysis and meta-regression of RCTs with 28,001 patients.
Published In:
Biomedical reports, 24(2), 23 (2026)
Database ID:
RPEP-15969

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-15969·https://rethinkpeptides.com/research/RPEP-15969

APA

Rampengan, Derren D C H; Surya, Stevanus C; Tjandra, Kevin C; Lele, Juan A J M N; Rampengan, Starry H; Kadariswantiningsih, Ika N; Idrisov, Bulat; Idrisova, Alina; Empitu, Maulana A. (2026). Cardiorenal safety and efficacy of angiotensin receptor-neprilysin inhibitors in heart failure across the ejection fraction spectrum: A meta-analysis and meta-regression of RCTs with 28,001 patients.. Biomedical reports, 24(2), 23. https://doi.org/10.3892/br.2025.2096

MLA

Rampengan, Derren D C H, et al. "Cardiorenal safety and efficacy of angiotensin receptor-neprilysin inhibitors in heart failure across the ejection fraction spectrum: A meta-analysis and meta-regression of RCTs with 28,001 patients.." Biomedical reports, 2026. https://doi.org/10.3892/br.2025.2096

RethinkPeptides

RethinkPeptides Research Database. "Cardiorenal safety and efficacy of angiotensin receptor-nepr..." RPEP-15969. Retrieved from https://rethinkpeptides.com/research/rampengan-2026-cardiorenal-safety-and-efficacy

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.